Diversification Versus Focus Dilemma Spotlights OTC Business Value
As the pharmaceutical industry's revenue hole deepens, CEOs face two main routes: banking on innovation, or diversifying through generics, OTC and other non-core businesses
As the pharmaceutical industry's revenue hole deepens, CEOs face two main routes: banking on innovation, or diversifying through generics, OTC and other non-core businesses